Procollagen III N-terminal Propeptide (PIIINP)
Procollagen III N-terminal propeptide (PIIINP) is a biomarker that reflects the synthesis of type III collagen, which is associated with liver fibrosis and hepatic remodeling.
PIIINP is a diagnostic marker for liver fibrosis and hepatic remodeling.
Key facts at a glance
- Units
- U/L
- Clinical utility
- diagnostic
- Result kind
- quantitative
- FDA-cleared
- Roche P3NP, UniQ P3NP
Procollagen III N-terminal propeptide (PIIINP) is a peptide cleaved from the procollagen III molecule during the formation of type III collagen. Type III collagen is a crucial component of the extracellular matrix in the liver, particularly during fibrogenesis.
Elevated levels of PIIINP in the blood are indicative of increased collagen synthesis, which is commonly associated with liver fibrosis. This makes PIIINP a valuable diagnostic tool for assessing the extent of liver damage and monitoring disease progression.
The reference range for PIIINP is typically 0–12 U/L. Levels above this range may suggest active fibrotic processes in the liver, prompting further investigation and potential intervention.
Frequently asked questions
What does a high PIIINP level mean?
How is PIIINP testing used in clinical practice?
Sources
- 1
- 2
Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy